FDA Antidepressant Data Was Fully Disclosed, Agency Tells Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Although there was internal disagreement on the implications of pediatric antidepressant data, all information was reviewed publicly, the agency maintains in a letter to the House Energy & Commerce/Oversight Subcommittee.
You may also be interested in...
Antidepressant Makers Expected To Testify At Sept. 9 Hearing On Trial Data Disclosure
House Commerce/Oversight Subcommittee Vice Chairman Greg Walden will oversee discussion of FDA, industry handling of data on antidepressant-related pediatric suicides.
Antidepressant Makers Expected To Testify At Sept. 9 Hearing On Trial Data Disclosure
House Commerce/Oversight Subcommittee Vice Chairman Greg Walden will oversee discussion of FDA, industry handling of data on antidepressant-related pediatric suicides.
House Antidepressant Hearing Rescheduled For Sept. 9
The hearing was postponed from July 20 when former subcommittee Chairman Greenwood accepted a position as BIO president. Witnesses could include seven antidepressant manufacturers.